Fresenius Medical Care AG & Co. KGaA (FMS) stock is soaring 7.81% in Tuesday's trading session following the release of its impressive first-quarter 2025 results. The German dialysis company reported better-than-expected earnings and revenue, demonstrating strong organic growth and improved profitability.
The company's Q1 2025 highlights include: - Organic revenue growth of 5%, driven by both Care Enablement and Care Delivery segments - Operating income grew 11% at constant currency, resulting in margin expansion - Reported net income increased by 113% - FME25 transformation program delivered EUR 68 million in additional sustainable savings
Investors were particularly encouraged by Fresenius Medical Care's confirmed full-year 2025 outlook, which projects positive revenue growth and a high-teens to high-twenties percent increase in operating income excluding special items. The company's ability to maintain stable U.S. same-market treatment growth despite a severe flu season also contributed to the positive market reaction. Analysts from Morgan Stanley and Deutsche Bank have noted the solid results, although some caution remains regarding U.S. dialysis treatment growth and potential foreign-currency exchange pressures on earnings estimates.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。